Skip to main
OMCL

Omnicell (OMCL) Stock Forecast & Price Target

Omnicell (OMCL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Omnicell is poised for strong growth in the coming years, driven by their innovative software and technology solutions that are transforming the pharmacy and nursing care delivery model. With a current P/E ratio of 11x NTM EBITDA estimates, Omnicell's stock is significantly undervalued compared to its historical average of 20x. The launch of their Titan XT series cabinets, which offers enhanced automation and AI features, is expected to drive incremental revenues and gain market share from their only major competitor, Pyxis. The recent FDA recall on Pyxis cabinets also presents a prime opportunity for Omnicell to convert customers and attract new ones. Despite some potential risks, such as economic recessions and cybersecurity concerns, the positive customer feedback and strong pipeline demand for their products bode well for Omnicell's future success. Therefore, this analyst has a favorable outlook on Omnicell's stock and has raised their price target to $70.

Bears say

Omnicell is experiencing strong bookings momentum and increased customer interest in their newer products, indicating potential for future revenue growth. However, their reliance on competitive conversions for a large portion of their bookings and the need to increase demo equipment could suggest that the market for their products is becoming more competitive. Additionally, their low profit margins and customer focus on cost-effective solutions may limit potential for significant profitability growth.

Omnicell (OMCL) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omnicell (OMCL) Forecast

Analysts have given Omnicell (OMCL) a Buy based on their latest research and market trends.

According to 5 analysts, Omnicell (OMCL) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omnicell (OMCL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.